# Sun Pharmaceutical Industries Limited trials: 60 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 60 trials with Sun Pharmaceutical Industries Limited as lead sponsor, 5 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Sun Pharmaceutical Industries Limited: 60 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/sun-pharmaceutical-industries-limited

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 60
- Recruiting or not yet: 5
- Read on: November 19, 2026

## Trials

The 25 newest of 60, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 27, 2026 | NCT07729579 | An Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the Face | Sun Pharmaceutical Industries Limited | Phase 1 | Recruiting | Actinic Keratosis (AK) | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729579) |
| February 4, 2026 | NCT07385547 | Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency | Sun Pharmaceutical Industries Limited | Phase 1 | Recruiting | Type II Diabetes Mellitus | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07385547) |
| December 15, 2025 | NCT07282743 | Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus | Sun Pharmaceutical Industries Limited | Phase 2 | Recruiting | Type II Diabetes Mellitus | 285 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07282743) |
| September 24, 2024 | NCT06611163 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. | Sun Pharmaceutical Industries Limited | Phase 3 | Active not recruiting | Moderate to Severe Genital Psoriasis | 206 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06611163) |
| May 23, 2024 | NCT06425900 | A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients | Sun Pharmaceutical Industries Limited | Phase 4 | Active not recruiting | Acne Vulgaris | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06425900) |
| May 16, 2024 | NCT06415305 | A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne | Sun Pharmaceutical Industries Limited | Phase 4 | Completed | Acne Vulgaris | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06415305) |
| May 16, 2024 | NCT06415292 | A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients | Sun Pharmaceutical Industries Limited | Phase 4 | Completed | Acne Vulgaris | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06415292) |
| May 16, 2024 | NCT06415279 | A Study to Evaluate the Reduction in Sebum (Skin Oil) Induced by Clascoterone Cream 1% in Acne Patients | Sun Pharmaceutical Industries Limited | Phase 4 | Completed | Acne Vulgaris | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06415279) |
| March 29, 2024 | NCT06336629 | A Study Assessing the Efficacy and Safety of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the... | Sun Pharmaceutical Industries Limited | Phase 4 | Completed | Acne Vulgaris | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06336629) |
| March 29, 2024 | NCT06336603 | A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne | Sun Pharmaceutical Industries Limited | Phase 4 | Completed | Acne Vulgaris | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06336603) |
| June 21, 2022 | NCT05422911 | Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. | Sun Pharmaceutical Industries Limited | Phase 2 | Recruiting | Metastatic Cancer, Neoplasm, Prostate, Castrate-sensitive, Castrate-sensitive Prostate Cancer | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05422911) |
| August 26, 2021 | NCT05022004 | A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension | Sun Pharmaceutical Industries Limited | Phase 3 | Completed | Primary Open Angle Glaucoma, Ocular Hypertension | 599 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05022004) |
| August 5, 2021 | NCT04991116 | Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis | Sun Pharmaceutical Industries Limited | Phase 3 | Active not recruiting | Psoriatic Arthritis | 529 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04991116) |
| December 24, 2020 | NCT04684485 | To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis | Sun Pharmaceutical Industries Limited | Phase 2 | Completed | Dermatitis, Atopic | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04684485) |
| September 28, 2020 | NCT04566666 | To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis | Sun Pharmaceutical Industries Limited | Phase 2 | Completed | Moderate to Severe Plaque Psoriasis | 263 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04566666) |
| August 10, 2020 | NCT04506463 | Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis | Sun Pharmaceutical Industries Limited | Phase 2 | Completed | Osteoarthritis of Knee | 397 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04506463) |
| April 22, 2020 | NCT04357795 | Effect of Cequa™ in Subjects With Dry Eye Disease | Sun Pharmaceutical Industries Limited | Phase 4 | Completed | Dry Eye Disease | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04357795) |
| March 19, 2020 | NCT04314544 | Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) | Sun Pharmaceutical Industries Limited | Phase 3 | Completed | Active Psoriatic Arthritis | 508 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04314544) |
| March 19, 2020 | NCT04314531 | Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) | Sun Pharmaceutical Industries Limited | Phase 3 | Active not recruiting | Active Psoriatic Arthritis | 296 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04314531) |
| August 26, 2019 | NCT04066504 | Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma | Sun Pharmaceutical Industries Limited | Observational | Completed | Basal Cell Carcinoma | 323 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04066504) |
| June 25, 2019 | NCT03997786 | A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis | Sun Pharmaceutical Industries Limited | Phase 2/3 | Active not recruiting | Moderate-to-severe Chronic Plaque Psoriasis | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03997786) |
| June 20, 2019 | NCT03992729 | Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab | Sun Pharmaceutical Industries Limited | Observational | Recruiting | Pregnancy Related | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03992729) |
| April 25, 2019 | NCT03927443 | A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension | Sun Pharmaceutical Industries Limited | Phase 3 | Withdrawn | Open Angle Glaucoma, Ocular Hypertension | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03927443) |
| April 1, 2019 | NCT03897088 | Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis | Sun Pharmaceutical Industries Limited | Phase 3 | Completed | Scalp Psoriasis | 231 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03897088) |
| April 1, 2019 | NCT03897075 | Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis | Sun Pharmaceutical Industries Limited | Phase 3 | Completed | Chronic Plaque Psoriasis, Moderate to Severe Nail Psoriasis | 99 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03897075) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 3 |
| Phase 1/2 | 2 |
| Phase 2 | 13 |
| Phase 2/3 | 3 |
| Phase 3 | 26 |
| Phase 4 | 11 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 39 |
| Withdrawn | 6 |
| Terminated | 5 |
| Active not recruiting | 5 |
| Recruiting | 5 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Acne Vulgaris | 7 |
| Dry Eye Syndromes | 4 |
| Keratoconjunctivitis Sicca | 4 |
| Prostatic Neoplasms | 3 |
| Diabetes Mellitus, Type 2 | 3 |
| Dermatitis, Atopic | 2 |
| Inflammation | 2 |
| Glaucoma, Open-Angle | 2 |
| Ocular Hypertension | 2 |
| Arthritis, Psoriatic | 2 |
| Motor Activity | 1 |
| Non-Radiographic Axial Spondyloarthritis | 1 |
| Osteoarthritis, Knee | 1 |
| Psoriasis | 1 |
| Neoplasm Metastasis | 1 |
| Carcinoma, Basal Cell | 1 |
| Asthma | 1 |
| Cataract | 1 |
| Schizophrenia | 1 |
| Bipolar Disorder | 1 |
| Stomatitis | 1 |
| Infertility | 1 |
| Keratosis, Actinic | 1 |
| Blepharitis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Tax preparation firms in the United States](https://specstream.ai/data/businesses/tax-preparation-firms/united-states)
- [Physical therapy clinics in the United States](https://specstream.ai/data/businesses/physical-therapy-clinics/united-states)
- [Japanese restaurants in the United States](https://specstream.ai/data/businesses/japanese-restaurants/united-states)
- [Exporters in the United States](https://specstream.ai/data/businesses/exporters/united-states)
- [Car manufacturers in the United States](https://specstream.ai/data/businesses/car-manufacturers/united-states)
